Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles
Source abstract
Abstract
Abstract Effectively delivering therapeutics for treating brain tumors is hindered by the physical and biological barriers in the brain. Even with the compromised blood–brain barrier and highly angiogenic blood–tumor barrier seen in glioblastoma (GBM), most drugs, including nanomaterial‐based formulations, hardly reach intracranial tumors. This work investigates sub‐5 nm ultrafine iron oxide nanoparticles (uIONP) with 3.5 nm core diameter as a carrier for delivering DNA topoisomerase inhibitor 7‐ethyl‐10‐hydroxyl camptothecin (SN38) to treat GBM. Given a higher surface‐to‐volume ratio, uIONP shows one‐ or three‐folds higher SN38 loading efficiency (48.3 ± 6.1%, mg/mg Fe) than those with core sizes of 10 or 20 nm. SN38 encapsulated in the coating polymer exhibits pH sensitive release with <10% over 48 h at pH 7.4, but 86% at pH 5, thus being protected from converting to inactive glucuronide by UDP‐glucuronosyltransferase 1A1. Conjugating αvβ3‐integrin‐targeted cyclo(Arg‐Gly‐Asp‐D‐Phe‐Cys) (RGD) as ligands, RGD‐uIONP/SN38 demonstrates targeted cytotoxicity to αvβ3‐integrin‐overexpressed U87MG GBM cells with a half‐maximal inhibitory concentration (IC50) of 30.9 ± 2.2 nm. The efficacy study using an orthotopic mouse model of GBM reveals tumor‐specific delivery of 11.5% injected RGD‐uIONP/SN38 (10 mg Fe kg−1), significantly prolonging the survival in mice by 41%, comparing to those treated with SN38 alone (p < 0.001).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Glioma Diagnosis and Treatment · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology and Imaging Sciences Emory University Atlanta GA 30329 USA
5M Biomed, LLC Atlanta GA 30303 USA
Department of Neurosurgery Emory University Atlanta GA 30329 USA
Division of Research Philadelphia College of Osteopathic Medicine – Georgia Campus Suwanee GA 30024 USA
Department of Pharmaceutical Sciences Philadelphia College of Osteopathic Medicine – Georgia Campus Suwanee GA 30024 USA
Funding
National Institutes of Health
References (95)
Show source-provided references
1. 10.3322/caac.2161310.3322/caac.21613 ↗
2. 10.1093/neuonc/noy13110.1093/neuonc/noy131 ↗
3. 10.1101/cshperspect.a02041210.1101/cshperspect.a020412 ↗
4. 10.1038/nrdp.2015.1710.1038/nrdp.2015.17 ↗
5. 10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗
6. 10.1073/pnas.95.8.460710.1073/pnas.95.8.4607 ↗
7. Monsky W. L. · Clin. Cancer Res. · 2002 · 8 · 1008
8. 10.1007/s11060-011-0564-y10.1007/s11060-011-0564-y ↗
9. 10.1038/nrd.2015.2110.1038/nrd.2015.21 ↗
10. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
11. 10.1002/adfm.20150418510.1002/adfm.201504185 ↗
12. 10.1016/j.tibtech.2018.01.00610.1016/j.tibtech.2018.01.006 ↗
13. 10.1002/adma.20210477910.1002/adma.202104779 ↗
14. 10.1021/acs.nanolett.9b0468310.1021/acs.nanolett.9b04683 ↗
15. 10.1038/nrn182710.1038/nrn1827 ↗
16. 10.1002/adtp.20200012410.1002/adtp.202000124 ↗
17. 10.1093/neuonc/nox17510.1093/neuonc/nox175 ↗
18. 10.1016/j.addr.2019.01.00510.1016/j.addr.2019.01.005 ↗
19. 10.1002/adma.20190653910.1002/adma.201906539 ↗
20. 10.1021/acs.molpharmaceut.6b0083910.1021/acs.molpharmaceut.6b00839 ↗
21. 10.3390/ijms14091750110.3390/ijms140917501 ↗
22. 10.1016/j.ejpb.2011.03.01610.1016/j.ejpb.2011.03.016 ↗
23. 10.1089/jamp.2013.111710.1089/jamp.2013.1117 ↗
24. 10.1038/s41467-018-05342-x10.1038/s41467-018-05342-x ↗
25. 10.3174/ajnr.A660010.3174/ajnr.A6600 ↗
26. 10.1148/radiol.201818120410.1148/radiol.2018181204 ↗
27. 10.3389/fnins.2018.0101910.3389/fnins.2018.01019 ↗
28. 10.3171/2016.1.JNS15159110.3171/2016.1.JNS151591 ↗
29. 10.1158/0008-5472.CAN-10-102210.1158/0008-5472.CAN-10-1022 ↗
30. 10.1227/NEU.0b013e31826989ef10.1227/NEU.0b013e31826989ef ↗
31. 10.3892/mco.2014.35610.3892/mco.2014.356 ↗
32. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
33. 10.1021/acsnano.7b0003810.1021/acsnano.7b00038 ↗
34. 10.7150/thno.3956010.7150/thno.39560 ↗
35. 10.1158/1078-0432.CCR-07-171910.1158/1078-0432.CCR-07-1719 ↗
36. 10.1074/jbc.M110.14750410.1074/jbc.M110.147504 ↗
37. 10.1038/sj.onc.120693510.1038/sj.onc.1206935 ↗
38. 10.1093/annonc/mdf33710.1093/annonc/mdf337 ↗
39. 10.1215/15228517-2008-07510.1215/15228517-2008-075 ↗
40. 10.2478/raon-2014-002110.2478/raon-2014-0021 ↗
41. 10.1039/C4TB00811A10.1039/C4TB00811A ↗
42. 10.1039/C4TB01828A10.1039/C4TB01828A ↗
43. 10.1016/j.colsurfb.2016.10.02610.1016/j.colsurfb.2016.10.026 ↗
44. 10.3390/polym601009310.3390/polym6010093 ↗
45. 10.1039/C6RA28502C10.1039/C6RA28502C ↗
46. 10.1021/ja803688x10.1021/ja803688x ↗
47. 10.1002/wnan.164410.1002/wnan.1644 ↗
48. 10.1517/1742524100360225910.1517/17425241003602259 ↗
49. 10.1021/ma500123g10.1021/ma500123g ↗
50. 10.7150/thno/v01p010210.7150/thno/v01p0102 ↗
51. 10.1186/1471-2407-11-29310.1186/1471-2407-11-293 ↗
52. 10.4049/jimmunol.170012810.4049/jimmunol.1700128 ↗
53. 10.1046/j.1523-1755.1999.055Suppl.69002.x10.1046/j.1523-1755.1999.055Suppl.69002.x ↗
54. 10.1042/BJ2010182510.1042/BJ20101825 ↗
55. 10.1016/j.cell.2016.12.03410.1016/j.cell.2016.12.034 ↗
56. 10.1016/j.tibs.2015.11.01210.1016/j.tibs.2015.11.012 ↗
57. 10.1038/s41419-020-2298-210.1038/s41419-020-2298-2 ↗
58. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
59. 10.1073/pnas.131912311010.1073/pnas.1319123110 ↗
60. 10.1007/s40262-018-0644-710.1007/s40262-018-0644-7 ↗
61. 10.1038/sj.tpj.650007210.1038/sj.tpj.6500072 ↗
62. 10.1039/C9TB00860H10.1039/C9TB00860H ↗
63. 10.1002/anie.20100732110.1002/anie.201007321 ↗
64. 10.2214/AJR.10.599210.2214/AJR.10.5992 ↗
65. 10.1158/1078-0432.CCR-10-342010.1158/1078-0432.CCR-10-3420 ↗
66. 10.1021/acs.chemrev.6b0007310.1021/acs.chemrev.6b00073 ↗
67. 10.1021/acs.chemrev.5b0014810.1021/acs.chemrev.5b00148 ↗
68. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
69. 10.3390/ijms2001009510.3390/ijms20010095 ↗
70. Chen Y. · Int. J. Oncol. · 2019 · 54 · 1143
71. 10.1158/1078-0432.CCR-09-239310.1158/1078-0432.CCR-09-2393 ↗
72. 10.1038/s41598-020-75253-910.1038/s41598-020-75253-9 ↗
73. 10.1021/acsnano.8b0440610.1021/acsnano.8b04406 ↗
74. 10.1101/cshperspect.a00647810.1101/cshperspect.a006478 ↗
75. 10.1007/s13277-012-0428-x10.1007/s13277-012-0428-x ↗
76. 10.1097/FTD.0b013e318068623b10.1097/FTD.0b013e318068623b ↗
77. 10.1073/pnas.091329010710.1073/pnas.0913290107 ↗
78. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
79. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
80. 10.1016/j.addr.2020.06.02510.1016/j.addr.2020.06.025 ↗
81. 10.1002/jhet.557040052710.1002/jhet.5570400527 ↗
82. 10.1177/088532821243788310.1177/0885328212437883 ↗
83. 10.1038/s41565-021-00858-810.1038/s41565-021-00858-8 ↗
84. Cooper G. M. · 2000
85. 10.1158/0008-5472.CAN-15-098810.1158/0008-5472.CAN-15-0988 ↗
86. 10.1158/1078-0432.CCR-05-213010.1158/1078-0432.CCR-05-2130 ↗
87. 10.1016/j.jpba.2012.01.00810.1016/j.jpba.2012.01.008 ↗
88. 10.1373/clinchem.2003.02348110.1373/clinchem.2003.023481 ↗
89. 10.1177/153537021453922710.1177/1535370214539227 ↗
90. 10.1021/acsnano.5b0128810.1021/acsnano.5b01288 ↗
91. 10.1074/jbc.M111.29360510.1074/jbc.M111.293605 ↗
92. 10.1038/s41598-020-68017-y10.1038/s41598-020-68017-y ↗
93. 10.1080/10717544.2019.158704510.1080/10717544.2019.1587045 ↗
94. 10.3390/pharmaceutics1111056910.3390/pharmaceutics11110569 ↗
95. 10.1016/j.biomaterials.2010.03.03610.1016/j.biomaterials.2010.03.036 ↗